Suppr超能文献

ATP6V0A1通过自噬-溶酶体途径保护帕金森病中的多巴胺能神经元。

ATP6V0A1 protects dopaminergic neurons via the autophagy-lysosomal pathway in Parkinson's disease.

作者信息

Lin Yuwan, Tan Zixin, Ye Wenfeng, Li Weimin, Chen Hao, Lin Yuping, Zhou Miaomiao, Liu Hanqun, Liu Qin, Zhang Zhiling, Kong Weixin, Xu Zongtang, Lin Hao, Mo Mingshu, Guo Wenyuan, Lin Keye, Tang Jiaxin, Zheng Yueying, Zhang Wenlong, Xu Pingyi, Chen Xiang

机构信息

Department of Neurology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong Province, China.

Department of Neurology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

出版信息

Neural Regen Res. 2025 Jun 19. doi: 10.4103/NRR.NRR-D-24-01420.

Abstract

Parkinson's disease is the second most common neurodegenerative disorder. ATPase H + transporting V0 subunit A1 (ATP6V0A1) is a component of vacuolar H + -ATPase (V-ATPase), an ATP-dependent proton pump. Our previous research identified an association between the ATP6V0A1 rs601999 variant and Parkinson's disease; however, the underlying mechanisms of ATP6V0A1 in Parkinson's disease remain elusive. In this study, we generated ATP6V0A1 knockdown and overexpression models and then examined the degeneration of dopaminergic neurons, lysosomal function, and the autophagy-lysosomal pathway using immunohistochemistry, western blotting, and transmission electron microscopy. We found that ATP6V0A1 protected against lysosomal dysfunction, regulated autophagic flux, and decreased phosphorylated α-synuclein levels in vitro . In vivo , ATP6V0A1 reduced levels of α-synuclein and phosphorylated α-synuclein proteins, mitigated degeneration of dopaminergic neurons, and improved motor dysfunction. Collectively, these findings show that ATP6V0A1 plays a protective role in Parkinson's disease by modulating the autophagy-lysosomal pathway. A correlation between ATP6V0A1 and Parkinson's disease susceptibility may serve as a biomarker for Parkinson's disease, while the protective effects of ATP6V0A1 could represent a potential therapeutic target for the disease.

摘要

帕金森病是第二常见的神经退行性疾病。ATP酶H⁺转运V0亚基A1(ATP6V0A1)是液泡H⁺-ATP酶(V-ATP酶)的一个组成部分,V-ATP酶是一种依赖ATP的质子泵。我们之前的研究确定了ATP6V0A1 rs601999变体与帕金森病之间的关联;然而,ATP6V0A1在帕金森病中的潜在机制仍不清楚。在本研究中,我们构建了ATP6V0A1基因敲低和过表达模型,然后使用免疫组织化学、蛋白质印迹法和透射电子显微镜检查多巴胺能神经元的变性、溶酶体功能以及自噬-溶酶体途径。我们发现,在体外,ATP6V0A1可防止溶酶体功能障碍,调节自噬通量,并降低磷酸化α-突触核蛋白水平。在体内,ATP6V0A1可降低α-突触核蛋白和磷酸化α-突触核蛋白的水平,减轻多巴胺能神经元的变性,并改善运动功能障碍。总的来说,这些发现表明,ATP6V0A1通过调节自噬-溶酶体途径在帕金森病中发挥保护作用。ATP6V0A1与帕金森病易感性之间的相关性可能作为帕金森病的生物标志物,而ATP6V0A1的保护作用可能代表该疾病的一个潜在治疗靶点。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验